title: Chemotherapy and patient co-morbidity in ventral site hernia development.
abstract: OBJECTIVE
  The risk factors associated with early ventral site hernia development following cancer surgery are ill defined and associated with an undetermined incidence.
  
  
  METHODS
  We analyzed 1,391 gynecologic cancer patient charts to identify the number of post-operative ventral site hernias over a nearly 6 year period. The following study variables were noted for evaluation: patient demographics, disease co-morbidity (hypertension, cardiovascular disease, diabetes), body mass index (BMI), treatment (e.g., chemotherapy regimen), intra-operative (e.g., bleeding) and postoperative (e.g., infection) complications, time to hernia development and length of hospital stay.
  
  
  RESULTS
  Twenty-six gynecologic cancer patients who developed a post-operative ventral hernia and subsequently underwent herniorrhaphy by our gynecologic oncology service were identified. The patient group's overall time to initial hernia development was 11.23 months. Following a multiple regression analysis, we found that treatment (e.g., bevacizumab, liposomal doxorubicin or radiotherapy associated with compromised wound healing [p=0.0186] and disease co-morbidity [0.0432]) were significant prognostic indicators for an accelerated time to hernia development. Moreover, five patients underwent treatment associated with compromised wound healing and also had disease co-morbidity. In this sub-group, post-operative hernia development occurred more rapidly (3.8 months) than the overall group of patients. BMI and age did not impact time to hernia development (p>0.05).
  
  
  CONCLUSIONS
  In the present gynecologic cancer patient series, a tendency for early post-operative hernia development appeared to coincide with treatment associated with compromised wound healing and disease co-morbidity. Gynecologic cancer surgeons should anticipate this potential complication and consider employing prophylactic intra-operative mesh to potentially prevent this condition.
authors.affiliation: Gynecologic Oncology Associates, Hoag Memorial Hospital Cancer Center, Newport Beach, CA, USA.
authors.forename: Mark A
authors.initials: MA
authors.lastname: Rettenmaier
authors.forename: Lisa N
authors.initials: LN
authors.lastname: Abaid
authors.forename: John V
authors.initials: JV
authors.lastname: Brown
authors.forename: John P
authors.initials: JP
authors.lastname: Micha
authors.forename: Bram H
authors.initials: BH
authors.lastname: Goldstein